Age | Intelligence quotient | Schizophrenia | Informed Consent | inpatient | Outpatients | olanzapine | Clozapine | Haloperidol | Risperidone | Flupenthixol | Fluphenazine
Item
patients (male or female, aged 18 to 65 years, qi>70) meeting the dsm-iv criteria (established by a senior psychiatrist) for schizophrenia and have the capacity to consent to the study. the study population include both inpatients and outpatients who are currently taking at least one of the following:olanzapine, clozapine, haloperidol, risperidone, flupenthixol, or fluphenazine. the following guidelines have been established for potential medication changes that patients may undergo during the course of the trial.
boolean
C0001779 (UMLS CUI [1])
C0456149 (UMLS CUI [2])
C0036341 (UMLS CUI [3])
C0021430 (UMLS CUI [4])
C0021562 (UMLS CUI [5])
C0029921 (UMLS CUI [6])
C0171023 (UMLS CUI [7])
C0009079 (UMLS CUI [8])
C0018546 (UMLS CUI [9])
C0073393 (UMLS CUI [10])
C0016367 (UMLS CUI [11])
C0016368 (UMLS CUI [12])
Medication dose changed
Item
dose changes to existing medication (either increases or decreases in dose) will be accepted and participants will be allowed to continue with the trial.
boolean
C1608430 (UMLS CUI [1])
Antipsychotic Agents Primary Change | Clinical Trial Withdrawal Patient need for
Item
a change in primary antipsychotics from one medication to another will require participants to withdrawn from the study.
boolean
C0040615 (UMLS CUI [1,1])
C0205225 (UMLS CUI [1,2])
C0392747 (UMLS CUI [1,3])
C0008976 (UMLS CUI [2,1])
C2349954 (UMLS CUI [2,2])
C0686904 (UMLS CUI [2,3])
Antipsychotic drug therapy | Antipsychotic Agent Secondary Addiction
Item
an addiction of another antipsychotic, secondary to the existing antipsychotic treatment (primary antipsychotic) will be acceptable providing that there isn't a complete change from one antipsychotic to another.
boolean
C1319421 (UMLS CUI [1])
C0040615 (UMLS CUI [2,1])
C0175668 (UMLS CUI [2,2])
C0085281 (UMLS CUI [2,3])
Pregnancy
Item
pregnancy
boolean
C0032961 (UMLS CUI [1])
Psychotic state Preventing Compliance behavior
Item
acute psychotic state, preventing the patient cooperation
boolean
C0459435 (UMLS CUI [1,1])
C1292733 (UMLS CUI [1,2])
C1321605 (UMLS CUI [1,3])
Comorbidity | Drug Dependence
Item
co-morbidity with drug dependency
boolean
C0009488 (UMLS CUI [1])
C1510472 (UMLS CUI [2])
Organic brain disorder | Disease Major
Item
organic cerebral disease, major somatic diseases
boolean
C4062280 (UMLS CUI [1])
C0012634 (UMLS CUI [2,1])
C0205164 (UMLS CUI [2,2])
Abnormal renal function | Liver Dysfunction | Thyroid function tests abnormal | Hematologic function Abnormal
Item
abnormal renal, hepatic, thyroid or hematological findings
boolean
C0151746 (UMLS CUI [1])
C0086565 (UMLS CUI [2])
C0476414 (UMLS CUI [3])
C0221130 (UMLS CUI [4,1])
C0205161 (UMLS CUI [4,2])
Mood regulation | Lithium | Valproate | topiramate | lamotrigine | Carbamazepine
Item
treatment with a regulator of mood(lithium, valproate, topiramate, lamotrigine et carbamazepine)
boolean
C0026516 (UMLS CUI [1,1])
C0598959 (UMLS CUI [1,2])
C0023870 (UMLS CUI [2])
C0080356 (UMLS CUI [3])
C0076829 (UMLS CUI [4])
C0064636 (UMLS CUI [5])
C0006949 (UMLS CUI [6])
Hypersensitivity Acetylcysteine
Item
allergy to nac
boolean
C0020517 (UMLS CUI [1,1])
C0001047 (UMLS CUI [1,2])
Antioxidants
Item
treatment with antioxidants
boolean
C0003402 (UMLS CUI [1])